Immunogen Earnings Preview: Get Ahead of the Analysts

Immunogen (NASDAQ:IMGN) will report earnings before markets open on Friday, April 26th. ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company’s tumor activated prodructs deliver chemotherapy specifically to a tumor. ImmunoGen has three drugs in clinical trials and is negotiating to take a drug into phase II trial. These products are being tested for the treatment of colorectal and small-cell lung cancer.

Here is your Cheat Sheet to Immunogen Earnings:

Earnings Expectations: Analysts expect earnings of $-0.15 per share on revenues of $11.94 million.

Analyst Trends:

Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a loss of $0.17 and has not changed. For the current year, the average estimate is a loss of $0.92, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Immunogen has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 40.25 27.99 13.94 19.30 16.36
Diluted EPS ($) -0.75 -0.63 -0.87 -0.85 -0.95

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 7.62 3.25 2.95 4.09 2.61
Diluted EPS ($) -0.17 -0.24 -0.28 -0.30 -0.29

Past Performance:
Immunogen has beat analyst estimates 2 times in the past four quarters. This is not consistent enough to get bullish yet.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]